文献速递颈动脉与弓上血管

经颈动脉血流反转保护下颈动脉支架术的安全性与有效性

Transcarotid Artery Revascularization With Flow Reversal.
PubMed 文献 · J Endovasc Ther · 2017-02-17

PROOF 研究评估经直接颈动脉入路、使用 ENROUTE 经颈动脉神经保护系统行血流反转下颈动脉支架术的安全性与有效性。2009 年 3 月至 2012 年 6 月共 75 例患者(平均年龄 72.6 岁,45 例男性,63 例无症状)接受该手术,30 天主要卒中、心肌梗死或死亡复合终点无事件发生,急性器械与手术成功率均为 90.6%。

要点

  • 30 天内无主要卒中、心肌梗死或死亡发生
  • 急性器械成功与手术成功均为 68/75(90.6%)
  • 反转血流回路建立于 71/75(94.6%),平均反转时间 19.1 分钟

核心结论

  • PROOF 研究结果表明,使用 ENROUTE 经颈动脉神经保护系统行经颈动脉血运重建是安全有效的。

研究设计与样本

  • 前瞻性研究,2009 年 3 月至 2012 年 6 月共纳入 75 例接受经颈动脉支架术患者,平均年龄 72.6 岁,45 例男性,63 例(84%)无症状。

主要发现

  • 30 天主要卒中、心肌梗死或死亡复合终点无事件发生;1 例发生次要卒中,判定与器械或手术无关。
  • 急性器械成功与手术成功均为 68 例(90.6%);反转血流回路建立于 71 例(94.6%)。
  • 仅 5 例出现短暂性血流反转不耐受,未影响手术完成;平均反转时间 19.1 分钟。
  • DW-MRI 亚组 56 例中 10 例(17.9%)出现同侧新发白质病灶,平均体积 0.17 mL。

临床怎么用

  • 对于适合经颈动脉入路的颈动脉狭窄患者,可考虑在 ENROUTE 系统血流反转保护下完成支架术。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To report a study evaluating the safety and efficacy of stenting via direct carotid access with flow reversal using the ENROUTE Transcarotid Neuroprotection System. METHODS: Between March 2009 and June 2012, 75 patients (mean age 72.6 years; 45 men) underwent carotid artery stenting with the ENROUTE System; the majority of patients (63, 84%) were asymptomatic. The primary safety endpoint was the composite of major stroke, myocardial infarction, or death at 30 days. Efficacy outcomes included acute device success, procedure success, and tolerance to flow reversal. Fifty-six (74.7%) patients underwent diffusion-weighted magnetic resonance imaging (DW-MRI) before and after the procedure to assess the development of new ischemic brain lesions. RESULTS: Acute device and procedure success were achieved in 68 (90.6%) patients. The reverse flow circuit was established in 71 (94.6%) patients; only 5 patients demonstrated transient intolerance to flow reversal that did not interfere with completion of the procedure. The mean time on flow reversal was 19.1 minutes. In the DW-MRI substudy, 10 (17.9%) of 56 patients had ipsilateral new white lesions with a mean volume of 0.17 mL. At 30 days, no major stroke, myocardial infarction, or death occurred; 1 patient had experienced a minor stroke that was adjudicated as not related to either the device or procedure. CONCLUSION: Results of the PROOF study demonstrate the safety and efficacy of transcarotid revascularization with the ENROUTE Transcarotid Neuroprotection System.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Alpaslan A, Wintermark M, Pintér L, et al. Transcarotid Artery Revascularization With Flow Reversal. J Endovasc Ther. 2017. PMID: 28335706. doi:10.1177/1526602817693607

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。